Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Clin Pharmacol Ther. 2021 Jul 7;110(3):649–661. doi: 10.1002/cpt.2327

Table 1.

Characteristics of implementers of clinical pharmacogenetics (individuals and institutions) that completed the survey

Individuals (n = 15)
Type of Training* n (%)
 PhD 2 (13%)
 PharmD 13 (87%)
 Master’s Degree 1 (7%)
Years Since Training Completed
 0–5 6 (40%)
 6–10 4 (27%)
 11–15 3 (20%)
 16 or more 2 (13%)
Pharmacogenetics Training*
 None 2 (13%)
 Fellowship 9 (60%)
 Master’s Degree 1 (7%)
 Residency 6 (40%)
 Seminars, Workshops, or CME 5 (33%)
 Online Training 2 (13%)
 Certificate Program 1 (7%)
Institutions (n = 13)
Type of Institution*
 Academic 11 (85%)
 Community 3 (23%)
Pharmacogenetic Testing Offered
 Broad 6 (46%)
 Limited 7 (54%)
 None 0 (0%)
*

More than one answer allowed

CME = continuing medical education